Cardiol Therapeutics Inc

CRDL

Company Profile

  • Business description

    Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.

  • Contact

    2265 Upper Middle Road East
    Suite 602
    OakvilleONL6H 0G5
    CAN

    T: +1 289 910-0850

    E: [email protected]

    https://www.cardiolrx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    18

Stocks News & Analysis

stocks

A top global stock to buy after a big change in its forecast

Undervalued by 24%, this wide-moat stock is a buy now.
stocks

Does the AI trade still have room to run?

Where Morningstar analysts see opportunities—and where they don’t.
stocks

More gas left in the tank for ASX highflyer

Shares jumped after results and are screening as overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,189.9015.700.17%
CAC 408,131.1511.90-0.15%
DAX 4024,933.0832.370.13%
Dow JONES (US)49,412.40313.690.64%
FTSE 10010,148.855.410.05%
HKSE26,765.5216.010.06%
NASDAQ23,601.36100.110.43%
Nikkei 22552,885.25961.62-1.79%
NZX 50 Index13,458.761.98-0.01%
S&P 5006,950.2334.620.50%
S&P/ASX 2008,860.1015.000.17%
SSE Composite Index4,132.603.56-0.09%

Market Movers